远大医药(00512.HK)创新药获批进入COVID-19 ARDS II期临床研究
远大医药(00512.HK)公布,集团在澳洲设立的全资附属Grand Medical正在开发的用於治疗脓毒症的全球创新药物STC3141,日前已分别获得批准在澳洲开展用於治疗感染2019冠状病毒病患者的急性呼吸窘迫综合症(COVID-19 ARDS)的II期临床研究和用於治疗脓毒症的Ib期临床研究。
COVID-19 ARDS的II期临床研究使得STC3141有望在COVID-19 ARDS治疗领域中成为全球研发进度最快的创新候选药物之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.